At a glance
ClinicalIndex Comparison RecordN/ACompleted· 991 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multi-Center, Non-Interventional Study, on the Efficacy of Dual and Triple Therapies Based on Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis C Patients
In Brief
An observational study for Hepatitis C, Chronic. Completed, enrolled 991 participants across 21 sites.
Detailed Summary
This multi-center, observational study will evaluate the efficacy and safety of dual and triple therapies based on Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C. Patients receiving treatment with either Pegasys plus ribavirin or Pegasys plus ribavirin plus telaprevir/boceprevir will be observed for the duration of their treatment and for up to 24 weeks of follow-up.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
CountriesIsrael
CollaboratorsClalit Health Services
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 2012
Enrollment StartMay 2012
Primary CompletionFeb 2016
TodayJul 2026
First PostedMay 23, 2012
Enrollment StartMay 28, 2012
Primary CompletionFeb 10, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.1 years ago